DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Candidiasis, Esophageal; HIV Infections

Intervention: L-743,872 (Drug)

Phase: N/A

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.


The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

Clinical Details

Official title: An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis

Study design: Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment

Detailed description: In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Male.


Inclusion Criteria You may be eligible for this study if you:

- Are an 18- to 65-year-old man with candidal esophagitis.

Locations and Contacts

Gary Calandra, Rahway, New Jersey 07065, United States
Additional Information

Last updated: June 23, 2005

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017